Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820756 | 1.00 | KDM4E (0.44) | KDM4EMAPTNPSR1ENPP2NPC1 | |
| SCHEMBL2825622 | 0.82 | KDM4E (0.46) | KDM4EMAPTNPSR1ENPP2NPC1 | |
| SCHEMBL2825619 | 0.82 | KDM4E (0.46) | KDM4EMAPTNPSR1ENPP2NPC1 | |
| SCHEMBL636791 | 0.80 | CYP1A2 (0.40) | KDM4EMAPTNPC1RAB9ARXFP1 | |
| SCHEMBL636792 | 0.80 | CYP1A2 (0.40) | KDM4EMAPTNPC1RAB9ARXFP1 | |
| SCHEMBL3958412 | 0.74 | ENPP2 (0.62) | KDM4EMAPTNPSR1ENPP2NPC1 | |
| SCHEMBL3959071 | 0.73 | FADS1 (0.48) | KDM4EMAPTNPSR1ENPP2NPC1 | |
| SCHEMBL15286911 | 0.71 | NPC1 (0.58) | KDM4EMAPTNPSR1NPC1RAB9A | |
| SCHEMBL3960302 | 0.71 | ENPP2 (0.52) | KDM4EMAPTNPSR1ENPP2NPC1 | |
| SCHEMBL3964209 | 0.71 | ENPP2 (0.55) | KDM4EMAPTNPSR1ENPP2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | claimed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | claimed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| WO-2009109987-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | TRPV3, TRPV1, TRPV5 | KDM4E 1749/4885MAPT 1674/4885NPSR1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.